Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis

Background: Infliximab (IFX) and vedolizumab (VDZ), frequently used biologics in inflammatory bowel disease (IBD), are available as intravenous (IV) and subcutaneous (SC) formulations; however, comparative data are limited. Objectives: To compare the rates of discontinuation due to lack of efficacy...

Cijeli opis

Bibliografski detalji

Glavni autori:	Marc Ferrante, Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, Jean-Frédéric Colombel, Silvio Danese, Roberto Faggiani, Jordi Guardiola, Stephen B. Hanauer, Jorgen Jahnsen, Walter Reinisch, Xavier Roblin, Philip J. Smith, Taek Sang Kwon, Seungmin Kim, Kyoungwan Nam, Raja Atreya
Format:	Artigo
Jezik:	Inglês
Izdano:	SAGE Publishing 2025-10-01
Serija:	Therapeutic Advances in Gastroenterology
Online pristup:	https://doi.org/10.1177/17562848251383767
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!